COMMUNIQUÉ DE PRESSE publié le 09/05/2024 à 14:00, il y a 6 mois 11 jours Volta Medical Featured in Latest Consensus Statement from Leading International Cardiac Electrophysiology Societies on Atrial Fibrillation Ablation Volta Medical featured in latest consensus statement by global cardiac electrophysiology societies on atrial fibrillation ablation, highlighting AI companion and TAILORED-AF trial Cardiac Electrophysiology Volta Medical Atrial Fibrillation Ablation Consensus Statement TAILORED-AF Trial
BRÈVE publiée le 18/04/2024 à 14:05, il y a 7 mois 2 jours Volta Medical présentera des résultats innovateurs en électrophysiologie cardiaque Intelligence Artificielle Essai Clinique Volta Medical Fibrillation Atriale Congrès Heart Rhythm
BRÈVE publiée le 18/04/2024 à 14:05, il y a 7 mois 2 jours Volta Medical will present innovative results in cardiac electrophysiology Artificial Intelligence Clinical Test Volta Medical Atrial Fibrillation Heart Rhythm Conference
COMMUNIQUÉ DE PRESSE publié le 18/04/2024 à 14:00, il y a 7 mois 2 jours Volta Medical Announces Late-Breaking TAILORED-AF Randomized Clinical Trial Results at Heart Rhythm 2024 in Boston, MA, USA Volta Medical announces late-breaking TAILORED-AF randomized clinical trial results at Heart Rhythm 2024 in Boston, featuring AI solutions for complex cardiac arrhythmias AI Solutions Volta Medical TAILORED-AF Randomized Clinical Trial Heart Rhythm 2024
COMMUNIQUÉ DE PRESSE publié le 18/04/2024 à 14:00, il y a 7 mois 2 jours Volta Medical annoncera les résultats de l’essai clinique randomisé TAILORED-AF lors des sessions Late-Breaking du congrès Heart Rhythm 2024 à Boston, MA, États-Unis Volta Medical annoncera les résultats de l'essai clinique TAILORED-AF lors du congrès Heart Rhythm 2024 à Boston. Présentations de la Prof. Deisenhofer et démonstration de Volta AF-Xplorer™ Intelligence Artificielle Essai Clinique Volta Medical Fibrillation Atriale TAILORED-AF
COMMUNIQUÉ DE PRESSE publié le 05/01/2023 à 09:30, il y a 1 année 10 mois Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced
Publié le 21/11/2024 à 06:58, il y a 6 heures 53 minutes Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 6 heures 53 minutes Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 6 heures 53 minutes Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 17 heures 44 minutes Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 18 heures 31 minutes Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Publié le 21/11/2024 à 13:30, il y a 21 minutes AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Publié le 21/11/2024 à 13:30, il y a 21 minutes Datametrex Secures Additional P.O. Approx $250K for IT Services
Publié le 21/11/2024 à 13:00, il y a 51 minutes Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Publié le 21/11/2024 à 13:00, il y a 51 minutes Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Publié le 21/11/2024 à 13:00, il y a 51 minutes Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Publié le 21/11/2024 à 13:41, il y a 10 minutes Original-Research: Pentixapharm Holding AG (von BankM AG): Kaufen
Publié le 21/11/2024 à 12:35, il y a 1 heure 16 minutes audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Publié le 21/11/2024 à 12:15, il y a 1 heure 36 minutes Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven